NCT00058890View on ClinicalTrials.gov

Gabapentin to Treat Itch in Patients With Liver Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Liver DiseaseCholestasisCirrhosisPruritusItching
Interventions
DRUG

Gabapentin

Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.

DRUG

Placebo

Trial Locations (1)

10032

Columbia University College of Physicians and Surgeons, New York

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease | Biotech Hunter | Biotech Hunter